Fisetin Dose-Response: Why 20 mg/kg Outperforms Lower Doses

Expert Summary

Fisetin's senolytic activity is dose-dependent with a clear threshold effect. In mouse studies, doses below ~50 mg/kg show anti-inflammatory and neuroprotective effects without significant senescent cell clearance, while doses of 100 mg/kg (equivalent to ~8–20 mg/kg in humans after allometric scaling) consistently reduce SA-β-Gal positive cells by 25–50%.

Key Facts

• Senolytic threshold: In the Yousefzadeh (2018) study, the senolytic dose in mice was 100 mg/kg. Using standard allometric scaling (divide by 12 for mouse-to-human conversion), this gives a human equivalent of ~8 mg/kg. The 20 mg/kg human protocol builds in a safety factor.
• Sub-threshold effects: At 5–10 mg/kg human equivalent doses, fisetin shows anti-inflammatory (NF-κB inhibition), neuroprotective (ERK/CREB activation), and antioxidant effects — beneficial but not senolytic.
• Dose-dependent SA-β-Gal reduction: At 100 mg/kg in mice, SA-β-Gal (senescence-associated beta-galactosidase, the gold standard senescence marker) is reduced by ~50%. At 50 mg/kg, reduction is ~25–30%. Below 25 mg/kg, effects are minimal.
• Human plasma levels: At 20 mg/kg oral dose in humans, peak fisetin plasma levels reach ~2–5 μM — within the range shown to inhibit BCL-2 family proteins in cell culture experiments (IC50: 1–10 μM).
• Bioavailability impact: With standard bioavailability of 10%, a 1,400 mg dose delivers ~140 mg absorbed — equivalent to perhaps 3–5 mg/kg effective dose. High-bioavailability forms (phytosome, liposomal) are critical to actually reaching senolytic plasma levels.
• Diminishing returns: Very high doses (>30 mg/kg human equivalent) do not appear to produce proportionally greater senolytic effects and increase risk of GI side effects.

Recommended Products

Frequently Asked Questions

Does taking more than 20 mg/kg provide additional senolytic benefit?

Evidence does not support significant additional benefit above the 20 mg/kg human protocol. GI tolerability decreases at higher doses without proportional senolytic improvement.

Can I use continuous low-dose fisetin as a substitute for burst dosing?

Low-dose continuous fisetin (100–200 mg/day) provides non-senolytic benefits but does not achieve senolytic plasma levels. Burst dosing is essential for senolytic action. Both approaches can be combined.

How do I know if my fisetin is reaching senolytic plasma levels?

At present, there is no convenient home test for plasma fisetin levels. Surrogate biomarkers (high-sensitivity CRP, IL-6, p16 mRNA from blood tests) may indicate senolytic activity over time.

Scientific References

• Yousefzadeh MJ et al. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine. 2018. PMID: 30279143
• Zhu Y et al. New agents that target senescent cells: the flavone, fisetin, and BCL-XL inhibitors. Aging. 2017. PMID: 28900009